Similar articles

• Azacitidine-associated Sweet's syndrome.

  Trickett HB, Cumpston A, Craig M. Trickett HB, et al. Am J Health Syst Pharm. 2012 May 15;69(10):869-71. doi: 10.2146/ajhp110523. Am J Health Syst Pharm. 2012. PMID: 22555082
• Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.

  Alencar C, Abramowtiz M, Parekh S, Braunshweig I, Jacobson M, Silverman L, Verma A. Alencar C, et al. Am J Hematol. 2009 Oct;84(10):688-9. doi: 10.1002/ajh.21510. Am J Hematol. 2009. PMID: 19722261 No abstract available.
• Azacitidine: a new medication associated with Sweet syndrome.

  Tintle S, Patel V, Ruskin A, Halasz C. Tintle S, et al. J Am Acad Dermatol. 2011 May;64(5):e77-9. doi: 10.1016/j.jaad.2010.06.032. J Am Acad Dermatol. 2011. PMID: 21496689 No abstract available.
• Distinct variant of Sweet's syndrome: bortezomib-induced histiocytoid Sweet's syndrome in a patient with multiple myeloma.

  Kim JS, Roh HS, Lee JW, Lee MW, Yu HJ. Kim JS, et al. Int J Dermatol. 2012 Dec;51(12):1491-3. doi: 10.1111/j.1365-4632.2011.05141.x. Epub 2012 Sep 24. Int J Dermatol. 2012. PMID: 22998496 Review. No abstract available.
• Response of autoimmune and inflammatory disorders in myelodysplastic syndromes to 5-azacytidine: report of two cases and literature review.

  Wu DY, Wang J, Zhang R, Yan XJ, Gao R. Wu DY, et al. Ann Palliat Med. 2021 Aug;10(8):9276-9280. doi: 10.21037/apm-21-1416. Ann Palliat Med. 2021. PMID: 34488413 Review.